Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-006183-45 | EudraCT Number | EudraCT |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To investigate safety, tolerability, pharmacokinetics including dose proportionality, and pharmacodynamics of BI 187004 CL within a predefined dose range
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BI 187004 CL | Experimental | 1 single dose per subject as oral solution |
|
| Placebo to BI 187004 CL | Placebo Comparator | 1 single dose per subject as oral solution |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo to BI 187004 CL | Drug | 1 single dose per subject as oral solution |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of adverse events | up to 15 days postdose |
| Measure | Description | Time Frame |
|---|---|---|
| Cmax (maximum measured concentration of the analyte in plasma) | up to 96 hours postdose | |
| AUC0-8 (area under the concentration-time curve of the in plasma over the time interval from 0 extrapolated to infinity) | up to 96 hours postdose |
Not provided
Inclusion criteria:
Exclusion criteria:
1. Any relevant deviation from healthy conditions
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 1307.1.1 Boehringer Ingelheim Investigational Site | Neuss | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34391480 | Derived | Bianzano S, Heise T, Jungnik A, Schepers C, Scholch C, Grafe-Mody U. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity. Clin Diabetes Endocrinol. 2021 Aug 15;7(1):16. doi: 10.1186/s40842-021-00130-x. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| BI 187004 CL |
| Drug |
1 single dose per subject as oral solution |
|
| AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point) | up to 96 hours postdose |